The week in health tech, explained in plain English.Get the free newsletter →
November 22, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

White House Plans $100M STEM PhD Push as NIH Sheds Scientists

The Trump administration plans to direct more than $100 million toward education programs for U.S. researchers in science, technology, engineering and math, Bloomberg reported Oct. 7. President Donald Trump is expected to announce the initiative at an Oct. 8 White House summit, an administration official told Bloomberg. The money will fund fellowships for science and engineering PhD students.

The timing matters. The investment arrives as the National Institutes of Health, the largest public funder of biomedical research in the world, loses scientists. That creates a tension at the heart of the announcement: the government is moving to build the next generation of researchers while the premier agency that trains and employs many of them is shedding talent.

For hospitals, academic medical centers, and biotech, the pipeline of PhD-trained scientists feeds drug discovery, clinical research, and health IT innovation. Fellowship dollars help early-career researchers, but they do not immediately replace senior expertise or restore lab capacity lost at the NIH. Watch for program details at the summit.

More in Government

Government

CMS Proposes Sweeping Medicare Advantage Changes for 2028

CMS's proposed 2028 rule would overhaul Medicare Advantage market entry, provider networks, and star ratings while adding a mandatory state-based payment model.

Why it matters: Medicare Advantage covers more than 35 million people, and these changes would reshape plan revenue, competition, and provider contracting.

Government

Michigan Pharmacy Owner Gets 82 Months in $5.6M Fraud Case

Michigan pharmacy owner Ali Naserdean was sentenced to 82 months for a $5.6 million payer fraud scheme and illegally distributing oxycodone, the DOJ said.

Why it matters: Pharmacy billing fraud and opioid diversion remain prime federal enforcement targets, raising the stakes for payer and health-system claims integrity.